BACE inhibitor

This page shows the latest BACE inhibitor news and features for those working in and with pharma, biotech and healthcare.

Eisai to tackle dementia in new US research facility

Merck &Co has also seen failure with its BACE1 inhibitor verubecestat, which also led to the drug’s abandonment. ... However Eisai, which also has a BACE inhibitor elenbecestat in late-stage testing, has several dementia candidates in its pipeline, and

Latest news

Daily Brief: PRIME status for vaccine, NHS urged to adopt automation, Brexit vote loom

Today’s biggest pharma news is more grim tidings from the field of Alzheimer’s research – AZ and Lilly have conceded defeat on their BACE inhibitor. ... Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat.
Daily Brief: PRIME status for vaccine, NHS urged to adopt automation, Brexit votes loom

Today’s biggest pharma news is more grim tidings from the field of Alzheimer’s research – AZ and Lilly have conceded defeat on their BACE inhibitor. ... Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat.
Merck BACE inhibitor adds to litany of Alzheimer's trial failures

Merck BACE inhibitor adds to litany of Alzheimer's trial failures. Interim data shows “ virtually no chance” of clinical success for verubecestat. ... The latest disappointment comes from a phase II/III study of Merck &Co's BACE inhibitor verubecestat
Biogen rises on more positive data for Alzheimer's candidate

compounds. Last week, it partnered with AstraZeneca (AZ) on MEDI1814, an antibody against amyloid-beta 42 (Aβ42) in phase I trials, and is also working with AZ on BACE inhibitor AZD3293,
Lilly taps AstraZeneca for another anti-amyloid drug

The two companies are already working together on AZD3293, a BACE inhibitor which is designed to interrupt the formation of Aβ at an early stage in the process, and are running ... secretase inhibitor semagacestat.

More from news
Approximately 2 fully matching, plus 25 partially matching documents found.

Latest Intelligence

Deal Watch table for September 2014

Licence and collaboration. Oral BACE inhibitor in phase I for Alzheimer's disease. ... TGR-1202 an oral P13K-delta inhibitor in phase II for haematological malignancies.
Pharma deals during September 2014

The product, an oral PK13 delta inhibitor appears to have completed phase 2 the stage when most options would expire. ... AstraZeneca and Lilly have announced a joint development and commercialisation deal for AstraZeneca's BACE inhibitor in phase I for
Eisai: Bucking the trend with R&D growth

BACE inhibitor E2609.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Home based, Editorial Team Leader, Medical Communications: Excellent package

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Home based, Senior Medical Writer, Medical Communications: Excellent package

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Editorial Director – Medical Education (MedComms): Neg

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Home based, Chief Medical Writer, Medical Communications: Excellent package

Business Unit Head, Medical Communications, London: Excellent package

Account Manager: £40, 000 - £45, 000 benefits

Senior Project Manager - Medical Writing: Great salary and bebefits

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Senior Account Manager: Competitive salary commensurate with experience

Healthcare PR Director: £100, 000 – £120, 000 benefits

Home based, Principal Medical Writer, Medical Communications: Excellent package

Client Services Director - Med Comms: Great salary and bebefits

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Delivery Manager/ Head of Delivery – Executive Search: Neg

Client Services Director – Healthcare Advertising - London: Neg

Subscribe to our email news alerts

PMHub

Add my company

Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....